There is increasing interest in combining targeted agents because of the growing understanding of the complexity and heterogeneity of the signalling networks controlling solid tumour growth. Such combination strategies are being used to inhibit multiple aberrant pathways in the hope of optimizing anti-tumour efficacy, but also to prevent development of resistance. Read more here.
Study mentioned: Park SR, et al. Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol. 2013 Jan 29. [Epub ahead of print] PMID: 23358316
No comments:
Post a Comment